Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 3/20 | 0.71 |
| ▸ | MEN1 | O00255 | 2/20 | 0.71 |
| ▸ | LMNA | P02545 | 2/20 | 0.71 |
| ▸ | MAPT | P10636 | 2/20 | 0.71 |
| ▸ | CDK8 | P49336 | 3/20 | 0.69 |
| ▸ | SAE1 | Q9UBE0 | 1/20 | 0.62 |
| ▸ | UBA2 | Q9UBT2 | 1/20 | 0.62 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.62 |
| ▸ | CA12 | O43570 | 1/20 | 0.62 |
| ▸ | CA1 | P00915 | 1/20 | 0.62 |
| ▸ | CA2 | P00918 | 1/20 | 0.62 |
| ▸ | CA9 | Q16790 | 1/20 | 0.62 |
| ▸ | GFER | P55789 | 1/20 | 0.62 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.61 |
| ▸ | HTT | P42858 | 1/20 | 0.61 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.61 |
| ▸ | KDR | P35968 | 5/20 | 0.61 |
| ▸ | TNNI3K | Q59H18 | 1/20 | 0.61 |
| ▸ | RAF1 | P04049 | 2/20 | 0.60 |
| ▸ | TP53 | P04637 | 1/20 | 0.60 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL259602 | 0.87 | SMN1; SMN2 (0.75) | KMT2AMEN1LMNAMAPTSAE1 | |
| SCHEMBL31054278 | 0.87 | SMN1; SMN2 (0.75) | KMT2AMEN1LMNAMAPTSAE1 | |
| SCHEMBL23051396 | 0.86 | KMT2A (0.58) | KMT2AMEN1LMNAMAPTCDK8 | |
| SCHEMBL12994776 | 0.86 | HPGD (0.65) | KMT2AMEN1LMNAMAPTCDK8 | |
| SCHEMBL21295380 | 0.86 | CA12 (0.71) | KMT2AMEN1LMNAMAPTMAPK1 | |
| SCHEMBL21295338 | 0.85 | TP53 (0.83) | KMT2AMEN1LMNAMAPTCDK8 | |
| SCHEMBL23051408 | 0.85 | KMT2A (0.57) | KMT2AMEN1LMNAMAPTCDK8 | |
| SCHEMBL22103809 | 0.85 | TP53 (0.77) | KMT2AMEN1LMNAMAPTCDK8 | |
| SCHEMBL29525913 | 0.85 | MAPT (0.61) | KMT2AMEN1LMNAMAPTCDK8 | |
| SCHEMBL22588908 | 0.84 | CA12 (0.72) | KMT2AMEN1LMNAMAPTMAPK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120009142-A1 | METHODS FOR TREATING HEPATITIS C | PTC THERAPEUTICS, INC. (US) | 2012-01-12 | — | — | US | disclosed |
| US-20110268698-A1 | METHODS FOR TREATING HEPATITIS C | PTC THERAPEUTICS, INC. (US) | 2011-11-03 | — | — | US | disclosed |
| US-8013006-B2 | Methods for treating hepatitis C | PTC THERAPEUTICS, INC. (US) | 2011-09-06 | — | — | US | disclosed |
| US-7973069-B2 | Methods for treating hepatitis C | PTC THERAPEUTICS, INC. (US) | 2011-07-05 | — | — | US | disclosed |
| US-20100305100-A1 | METHODS FOR TREATING HEPATITIS C | PTC THERAPEUTICS, INC. (US) | 2010-12-02 | — | — | US | disclosed |
| US-20100292187-A1 | METHODS FOR TREATING HEPATITIS C | PTC THERAPEUTICS, INC. (US) | 2010-11-18 | — | — | US | disclosed |
| US-20080096928-A9 | Indole compounds that modify translational control of Hepatitis C virus | PTC THERAPEUTICS, INC. | 2008-04-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080096928-A9 | Indole compounds that modify translational control of Hepatitis C virus | EIF2AK2, INMT, IDO1 | KMT2A 1335/4885MEN1 4550/4885LMNA 4373/4885 |
| US-20110268698-A1 | METHODS FOR TREATING HEPATITIS C | HAVCR2, LIPC, HCCS | KMT2A 4617/4885MEN1 4825/4885LMNA 1241/4885 |
| US-20120009142-A1 | METHODS FOR TREATING HEPATITIS C | OAT, HAVCR2, HCCS | KMT2A 3974/4885MEN1 4815/4885LMNA 3101/4885 |
| US-20100292187-A1 | METHODS FOR TREATING HEPATITIS C | HAVCR2, EIF2AK2, MAVS | KMT2A 4464/4885MEN1 4800/4885LMNA 1012/4885 |
| US-20100305100-A1 | METHODS FOR TREATING HEPATITIS C | HAVCR2, EIF2AK2, MAVS | KMT2A 4464/4885MEN1 4800/4885LMNA 1012/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.